TY - JOUR
T1 - Next-Generation Sequencing of Lung Cancers
T2 - Lessons Learned and Future Directions
AU - Devarakonda, Siddhartha
AU - Masood, Ashiq
AU - Govindan, Ramaswamy
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer continue to have poor outcomes. The ability to comprehensively characterize the genomic alterations in various subtypes of lung cancer has the potential to transform cancer care by facilitating the identification of novel treatment strategies. The objective of this review is to summarize key findings from recent studies that have sequenced a large number of lung cancer samples and discuss the diagnostic, prognostic, and therapeutic relevance of these findings.
AB - Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer continue to have poor outcomes. The ability to comprehensively characterize the genomic alterations in various subtypes of lung cancer has the potential to transform cancer care by facilitating the identification of novel treatment strategies. The objective of this review is to summarize key findings from recent studies that have sequenced a large number of lung cancer samples and discuss the diagnostic, prognostic, and therapeutic relevance of these findings.
KW - Lung cancer
KW - Sequencing
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84998953802&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2016.08.008
DO - 10.1016/j.hoc.2016.08.008
M3 - Review article
C2 - 27912825
AN - SCOPUS:84998953802
SN - 0889-8588
VL - 31
SP - 1
EP - 12
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -